Novel splice site CACNA1A mutation causing episodic ataxia type 2
- PMID: 14530926
- DOI: 10.1007/s10048-003-0161-0
Novel splice site CACNA1A mutation causing episodic ataxia type 2
Abstract
Episodic ataxia type 2 (EA-2) is an autosomal dominant neurological disorder, characterized by episodes of ataxia, vertigo, nausea, nystagmus, and fatigue, associated with acetazolamide responsiveness. The disease is caused by mutations in the P/Q-type calcium channel Ca(v)2.1 subunit gene, CACNA1A, located on chromosome 19p13.2. We analyzed a family with 13 affected individuals for linkage to this locus and reached a two-point maximum LOD score of 4.48. A novel CACNA1A mutation, IVS36-2A>G, at the 3' acceptor splice site of intron 36 was identified by sequencing. It is the first described CACNA1A acceptor splice site mutation and the most C-terminal EA-2-causing mutation reported to date.
Similar articles
-
Episodic ataxia type 2: phenotype characteristics of a novel CACNA1A mutation and review of the literature.J Neurol. 2014 May;261(5):983-91. doi: 10.1007/s00415-014-7310-2. J Neurol. 2014. PMID: 24658662 Review.
-
New calcium channel mutations predict aberrant RNA splicing in episodic ataxia.Neurology. 2005 Jul 26;65(2):308-10. doi: 10.1212/01.wnl.0000169020.82223.dd. Neurology. 2005. PMID: 16043807
-
A new CACNA1A gene mutation in acetazolamide-responsive familial hemiplegic migraine and ataxia.Neurology. 1999 Jul 13;53(1):38-43. doi: 10.1212/wnl.53.1.38. Neurology. 1999. PMID: 10408534
-
A novel nonsense mutation in CACNA1A causes episodic ataxia and hemiplegia.Neurology. 1999 Jul 13;53(1):34-7. doi: 10.1212/wnl.53.1.34. Neurology. 1999. PMID: 10408533
-
Episodic ataxia type 1 and 2 (familial periodic ataxia/vertigo).Audiol Neurootol. 1997 Nov-Dec;2(6):373-83. doi: 10.1159/000259262. Audiol Neurootol. 1997. PMID: 9390841 Review.
Cited by
-
Migraine genetics: an update.Curr Pain Headache Rep. 2005 Jun;9(3):213-20. doi: 10.1007/s11916-005-0065-9. Curr Pain Headache Rep. 2005. PMID: 15907261 Review.
-
CACNA1A haploinsufficiency causes cognitive impairment, autism and epileptic encephalopathy with mild cerebellar symptoms.Eur J Hum Genet. 2015 Nov;23(11):1505-12. doi: 10.1038/ejhg.2015.21. Epub 2015 Mar 4. Eur J Hum Genet. 2015. PMID: 25735478 Free PMC article.
-
Targeting Alternative Splicing as a Potential Therapy for Episodic Ataxia Type 2.Biomedicines. 2020 Sep 5;8(9):332. doi: 10.3390/biomedicines8090332. Biomedicines. 2020. PMID: 32899500 Free PMC article. Review.
-
Episodic ataxia type 2: phenotype characteristics of a novel CACNA1A mutation and review of the literature.J Neurol. 2014 May;261(5):983-91. doi: 10.1007/s00415-014-7310-2. J Neurol. 2014. PMID: 24658662 Review.
-
Alternative Splicing and CaV-Associated Channelopathies.Wiley Interdiscip Rev RNA. 2025 May-Jun;16(3):e70016. doi: 10.1002/wrna.70016. Wiley Interdiscip Rev RNA. 2025. PMID: 40490926 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources